Eli Lilly’s Verzenio is already one of its fastest-growing products, but could go up another gear following a pair of FDA approvals that expand its eligible patient population – particularly ...

The benefit of adjuvant Verzenio in combination with endocrine therapy continues to deepen with additional follow-up, now demonstrating an absolut ...

Combining imlunestrant with Verzenio enhanced PFS in both ESR1-mutated and non-mutated populations, outperforming imlunestrant monotherapy. Safety profiles for imlunestrant and its combination with ...

Eli Lilly’s Verzenio just made life incrementally harder for Pfizer’s market-leading Ibrance, thanks to a reimbursement green light in England for the postsurgery treatment of early breast cancer.